Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.44 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030136 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL7031536 | 0.90 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL7031537 | 0.90 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6850331 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6696906 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6689935 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6696900 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6850277 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6690204 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6690206 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1283200-A2 | Optically pure paroxetine precursors | Astur-Pharma, S.A. (ES) | 2003-02-12 | — | — | EP | disclosed |
| US-20030018048-A1 | Optically pure paroxetine precursors | ASTUR PHARMA | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018048-A1 | Optically pure paroxetine precursors | TPH1, TPH2, MAOB | SMN1; SMN2 4526/4885NPC1 4061/4885RAB9A 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.